Search

Displaying results 2491 - 2500 of 8974 in total
  1. Drug

    Grazoprevir

    go.drugbank.com/drugs/DB11575
    Approved

    The barrier for develoment of resistance to NS3/4A inhibitors is lower than that of NS5B inhibitors, another class of DAAs [A19593]. … When combined together, Grazoprevir and [DB11574] as the combination product Zepatier have been shown to achieve a SVR between 94% and 97% for genotype 1 and 97% and 100% for genotype 4 after 12 weeks

    Categories: Antivirals for Systemic Use, Antiinfectives for Systemic Use
  2. Drug

    Venlafaxine

    go.drugbank.com/drugs/DB00285
    ApprovedInvestigational

    Venlafaxine is officially approved to treat major depressive disorder (MDD), generalized anxiety disorder (GAD), social anxiety disorder, and panic disorder in adults. … for the management of neuropathic pain (although there is only minimal evidence of efficacy for this condition).

    Categories: Antidepressive Agents Indicated for Depression, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  3. Drug

    Ponesimod

    go.drugbank.com/drugs/DB12016
    ApprovedInvestigational

    [A232079] Fingolimod's activity at sphingosine 1-phosphate receptor 3 was suspected to be responsible for a portion of it's adverse effects, and so more selective modulators were developed. … [A232079,L32709] Ponesimod was developed out of a need for a more selective modulator of sphingosine 1-phosphate receptor 1 than [fingolimod].

  4. Drug

    Metaxalone

    go.drugbank.com/drugs/DB00660
    ApprovedInvestigational

    Metaxalone is a moderate to strong muscle relaxant used in the symptomatic treatment of musculoskeletal pain caused by strains, sprains, and other musculoskeletal conditions. … It is marketed by King Pharmaceuticals under the brand name Skelaxin®. Its main mechanism of action is thought to involve general central nervous system depression.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates
  5. Drug

    Amifampridine

    go.drugbank.com/drugs/DB11640
    Approved

    Firdapse (amifampridine) was formally approved by the US FDA for the treatment of adults with LEMS as recently as November of 2018 [L4819]. … Amifampridine phosphate is a more stable salt that serves as an active ingredient of EMA-approved Firdapse, which was previously marketed as Zenas.

  6. Drug

    Somatrem

    go.drugbank.com/drugs/DB09098
    ApprovedWithdrawn

    continues to be mired in persistent bioethical debate [A32292]. … Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents

  7. Drug

    Dimethyl sulfoxide

    go.drugbank.com/drugs/DB01093
    ApprovedInvestigationalVet approved

    Because of its ability to penetrate biological membranes, it is used as a vehicle for topical application of pharmaceuticals. It is also used to protect tissue during cryopreservation.

    Synonyms: S(O)Me2Categories: Topical Products for Joint and Muscular Pain, Compounds used in a research, industrial, or household setting
  8. Drug

    Propylhexedrine

    go.drugbank.com/drugs/DB06714
    Approved

    It is used to give temporary relief for nasal congestion from colds, allergic rhinitis, or allergies.

  9. Drug

    Phenolphthalein

    go.drugbank.com/drugs/DB04824
    ApprovedWithdrawn

    Phenolphthalein was withdrawn in Canada due to concerns with carcinogenicity in 1997.

    Mixtures: Lax-BO Tab, Herbalax Forte No 70 TabCategories: Drugs for Constipation, Compounds used in a research, industrial, or household setting
  10. Drug

    Cysteine

    go.drugbank.com/drugs/DB00151
    ApprovedInvestigationalNutraceutical

    A thiol-containing non-essential amino acid that is oxidized to form cystine.

    Mixtures: NEPHROSTERIL FOR INTRAVENOUS INFUSION, AMINOSTERIL N-HEPA FOR INTRAVENOUS INFUSION 8%